Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · IEX Real-Time Price · USD
267.55
+3.58 (1.36%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for BIO stock have an average target of 410, with a low estimate of 365 and a high estimate of 480. The average target predicts an increase of 53.24% from the current stock price of 267.55.
Analyst Consensus: Buy
* Price targets were last updated on May 8, 2024.
Analyst Ratings
The average analyst rating for BIO stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $420 → $385 | Strong Buy | Maintains | $420 → $385 | +43.90% | May 8, 2024 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $400 → $365 | Strong Buy → Hold | Downgrades | $400 → $365 | +36.42% | Apr 3, 2024 |
| UBS | UBS | Strong Buy Maintains $395 → $420 | Strong Buy | Maintains | $395 → $420 | +56.98% | Feb 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $484 → $480 | Buy | Maintains | $484 → $480 | +79.41% | Feb 16, 2024 |
| UBS | UBS | Strong Buy Initiates $395 | Strong Buy | Initiates | $395 | +47.64% | Dec 7, 2023 |
Financial Forecast
Revenue This Year
2.68B
from 2.67B
Increased by 0.25%
Revenue Next Year
2.82B
from 2.68B
Increased by 5.27%
EPS This Year
10.54
from -21.82
EPS Next Year
11.96
from 10.54
Increased by 13.53%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.8B | 3.0B | 3.1B | 3.1B | 3.3B |
| Avg | 2.7B | 2.8B | 2.9B | 3.0B | 3.1B |
| Low | 2.6B | 2.7B | 2.8B | 2.9B | 3.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.0% | 12.1% | 10.4% | 7.3% | 8.1% |
| Avg | 0.3% | 5.3% | 4.1% | 3.2% | 4.0% |
| Low | -4.3% | 0.2% | -0.6% | 0.1% | 0.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.75 | 12.69 | 14.70 | 13.56 | 14.61 |
| Avg | 10.54 | 11.96 | 13.46 | 13.04 | 14.05 |
| Low | 9.94 | 11.22 | 12.30 | 12.65 | 13.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 20.5% | 22.9% | 0.7% | 12.0% |
| Avg | - | 13.5% | 12.6% | -3.2% | 7.7% |
| Low | - | 6.5% | 2.9% | -6.0% | 4.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.